CN Bio
CN Bio is a leading bioengineering company specialising in single and multi-organ microphysiological systems and innovative lab technologies. We aim to provide systems that generate clinically translatable data that can enhance the development of tomorrow’s medicines. We help Pharma and Biotech Companies to improve the effectiveness and efficiency of preclinical drug testing and Academia to discover more about human physiology. Our microphysiological systems (also known as Organ-on-Chip) bring precision and human-relevant data to drug development and other commercial or research scenarios. They enable researchers to work on novel and innovative human modalities including gene editing, therapeutic antibodies, proteins and cellular therapies.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Nationally (across the country)
Our Vision
CN Bio’s vision is for PhysioMimix™ technology to be the engine that drives the development of new medicines and consumer products which are safer and more effective by enabling a new understanding of human biology in the laboratory. Our human tissue-based studies provide quicker, more predictive data than traditional approaches, enabling teams to decide with confidence which projects to invest in.
Our Technology
We work closely with leading academic bio-engineering groups including MIT (Massachusetts Institute of Technology) and Vanderbilt University. CN Bio has been awarded numerous prestigious grants by sponsors including Innovate UK and was a participant in the DARPA (United States Defence Advanced Research Projects agency) Body-on-a-Chip project.
Our technology is being used by scientists at the US FDA (Food and Drug Administration) to investigate drug metabolism, toxicity and drug-drug interactions.